LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study
Fuzhe Wang, Sheng Chen, Lingshuang Sheng, Zi‐Xun Yan et al.
Journal
Blood
Topics
CAR-T cell therapy research
article
LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study
Fuzhe Wang, Sheng Chen, Lingshuang Sheng, Zi‐Xun Yan, Xiaowei Xu, Xuanming Yang, Yilun Zhang, Qi Song, Hongmei Yi, Wang Li, Lei Li, Jianyong Li, Shu Cheng, Pengpeng Xu, Wen Wu, Yuxiang Zhu, Rong Shen, Weiguo Cao, Xufeng Jiang, Wei Zhao, Li Wang
article en
Abstract
No abstract available for this paper.
Publication Tag
BloodVol. 144(Supplement 1)
Institutions
Shanghai Jiao Tong University (CN), Ruijin Hospital (CN), Shanghai Institute of Hematology (CN), Jiangsu Province Hospital (CN), State Key Laboratory of Medical Genomics, Nanjing Medical University (CN)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study — Fuzhe Wang, Sheng Chen, et al. · Blood (2024) | TGRS Research Map | TGRS